Saleem A, Jeyaseelan V, Kazi Z, Zehra M, Alam M, Macklin G
Lancet Reg Health Southeast Asia. 2025; 33:100531.
PMID: 39902295
PMC: 11788853.
DOI: 10.1016/j.lansea.2025.100531.
Snider C, Zaman K, Estivariz C, Aziz A, Yunus M, Haque W
Vaccine. 2024; 42(22):126216.
PMID: 39146859
PMC: 11460026.
DOI: 10.1016/j.vaccine.2024.126216.
Xu J, Liu Y, Qiu W, Li W, Hu X, Li X
BMC Infect Dis. 2024; 24(1):535.
PMID: 38807038
PMC: 11131326.
DOI: 10.1186/s12879-024-09389-8.
Mohanty L, John T, Pawar S, Venkat Ramanan P, Agarkhedkar S, Haldar P
Vaccines (Basel). 2024; 12(4).
PMID: 38675806
PMC: 11054616.
DOI: 10.3390/vaccines12040424.
Hussain I, Umer M, Khan A, Sajid M, Ahmed I, Begum K
Front Public Health. 2024; 12:1384410.
PMID: 38601488
PMC: 11004230.
DOI: 10.3389/fpubh.2024.1384410.
Poliovirus-Neutralizing Antibody Seroprevalence and Vaccine Habits in a Vaccine-Derived Poliovirus Outbreak Region in the Democratic Republic of Congo in 2018: The Impact on the Global Eradication Initiative.
Halbrook M, Gadoth A, Mukadi P, Hoff N, Musene K, Dzogang C
Vaccines (Basel). 2024; 12(3).
PMID: 38543880
PMC: 10975469.
DOI: 10.3390/vaccines12030246.
Nutritional Status Link with Polioseronegativity Among Children from Poliomyelitis Transmission High-Risk Area of the Democratic Republic of the Congo (DRC).
Mwamba G, Nzaji M, Hoff N, Mukadi P, Musene K, Gerber S
J Multidiscip Healthc. 2024; 17:1219-1229.
PMID: 38524863
PMC: 10960541.
DOI: 10.2147/JMDH.S437351.
Safety of the novel oral poliovirus vaccine type 2 (nOPV2) in infants and young children aged 1 to <5 years and lot-to-lot consistency of the immune response to nOPV2 in infants in The Gambia: a phase 3, double-blind, randomised controlled trial.
Ochoge M, Futa A, Umesi A, Affleck L, Kotei L, Daffeh B
Lancet. 2024; 403(10432):1164-1175.
PMID: 38402887
PMC: 10985839.
DOI: 10.1016/S0140-6736(23)02844-1.
Seroprevalence of poliovirus antibodies in Nigeria: refining strategies to sustain the eradication effort.
Bolu O, Adamu U, Franka R, Umeokonkwo C, An Q, Greby S
Pan Afr Med J. 2024; 45(Suppl 2):2.
PMID: 38370104
PMC: 10874096.
DOI: 10.11604/pamj.supp.2023.45.2.38098.
Plaque Reduction Neutralization Test (PRNT) Accuracy in Evaluating Humoral Immune Response to SARS-CoV-2.
Horbach I, Azevedo A, Schwarcz W, Alves N, de Moura Dias B, Setatino B
Diseases. 2024; 12(1).
PMID: 38248380
PMC: 10814169.
DOI: 10.3390/diseases12010029.
Tolerability, safety, and immunogenicity of the novel oral polio vaccine type 2 in children aged 6 weeks to 59 months in an outbreak response campaign in The Gambia: an observational cohort study.
Bashorun A, Kotei L, Jawla O, Jallow A, Saidy A, Kinteh M
Lancet Infect Dis. 2024; 24(4):417-426.
PMID: 38237616
PMC: 10954559.
DOI: 10.1016/S1473-3099(23)00631-X.
Poliovirus serological assay after the cVDPV1 outbreak in Papua New Guinea: a cross-sectional study from 2020 to 2021.
Pomat W, Lopez Cavestany R, Jeyaseelan V, Ford R, Gare J, Avagyan T
Lancet Reg Health West Pac. 2024; 44:100986.
PMID: 38204497
PMC: 10777103.
DOI: 10.1016/j.lanwpc.2023.100986.
Safety and immunogenicity of shorter interval schedules of the novel oral poliovirus vaccine type 2 in infants: a phase 3, randomised, controlled, non-inferiority study in the Dominican Republic.
Mejia L, Mendez L, Bandyopadhyay A, Gast C, Mazara S, Rodriguez K
Lancet Infect Dis. 2023; 24(3):275-284.
PMID: 38109921
PMC: 10881405.
DOI: 10.1016/S1473-3099(23)00519-4.
Persistence of immunity following a single dose of inactivated poliovirus vaccine: a phase 4, open label, non-randomised clinical trial.
Sharma A, Verma H, Estivariz C, Bajracharaya L, Rai G, Shah G
Lancet Microbe. 2023; 4(11):e923-e930.
PMID: 37774729
PMC: 10976347.
DOI: 10.1016/S2666-5247(23)00215-X.
Poliovirus type 1 systemic humoral and intestinal mucosal immunity induced by monovalent oral poliovirus vaccine, fractional inactivated poliovirus vaccine, and bivalent oral poliovirus vaccine: A randomized controlled trial.
Snider C, Zaman K, Wilkinson A, Aziz A, Yunus M, Haque W
Vaccine. 2023; 41(41):6083-6092.
PMID: 37652822
PMC: 10895964.
DOI: 10.1016/j.vaccine.2023.08.055.
Assessment of Enterovirus Excretion and Identification of VDPVs in Patients with Primary Immunodeficiency in India: Outcome of ICMR-WHO Collaborative Study Phase-I.
Mohanty M, Desai M, Mohammad A, Aggarwal A, Govindaraj G, Bhattad S
Vaccines (Basel). 2023; 11(7).
PMID: 37515027
PMC: 10383878.
DOI: 10.3390/vaccines11071211.
Poliovirus antibodies following two rounds of campaigns with a type 2 novel oral poliovirus vaccine in Liberia: a clustered, population-based seroprevalence survey.
Kennedy S, Macklin G, Mason Ross G, Lopez Cavestany R, Moukom R, Jones K
Lancet Glob Health. 2023; 11(6):e917-e923.
PMID: 37202026
PMC: 10187988.
DOI: 10.1016/S2214-109X(23)00116-X.
Immunogenicity of novel oral poliovirus vaccine type 2 administered concomitantly with bivalent oral poliovirus vaccine: an open-label, non-inferiority, randomised, controlled trial.
Wilkinson A, Zaman K, Hoque M, Estivariz C, Burns C, Konopka-Anstadt J
Lancet Infect Dis. 2023; 23(9):1062-1071.
PMID: 37178706
PMC: 10503264.
DOI: 10.1016/S1473-3099(23)00139-1.
Immuno-Colorimetric Neutralization Test: A Surrogate for Widely Used Plaque Reduction Neutralization Tests in Public Health Virology.
Vaidya S
Viruses. 2023; 15(4).
PMID: 37112919
PMC: 10143445.
DOI: 10.3390/v15040939.
Using Dried Blood Spots for a Sero-Surveillance Study of Maternally Derived Antibody against Group B Streptococcus.
Auma E, Hall T, Chopra S, Bilton S, Ramkhelawon L, Amini F
Vaccines (Basel). 2023; 11(2).
PMID: 36851236
PMC: 9966576.
DOI: 10.3390/vaccines11020357.
